Meeting
2016 Genitourinary Cancers Symposium
Combined Akt and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer.
Authors
Paul Toren
University of Laval, Québec, QC, Canada
Paul Toren , Soojin Kim , Ladan Fazli , Barry Davies , Martin Gleave , Amina Zoubeidi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 192)
DOI
10.1200/jco.2016.34.2_suppl.192
Abstract #
192
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Preclinical evaluation of teleglenastat (CB-839) in prostate cancer.
First Author: Elaine T. Lam
Poster
2023 ASCO Genitourinary Cancers Symposium
Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.
First Author: Adrish Sen
Poster
2022 ASCO Genitourinary Cancers Symposium
Patient derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for management of metastatic castrate resistant prostate cancer.
First Author: Adam McLain Kase
Poster
2021 Genitourinary Cancers Symposium
A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
First Author: Neal D. Shore